W. A. L. van Otterlo et al. / Tetrahedron Letters 45 (2004) 5091–5094
5093
Tatsuta and co-workers11 and Pandya et al.,5 for the
formation of the alternative regioisomer 3 from 1.
Therefore, in addition to the regioisomer of medermycin
suggested by Morin and co-workers1 it is also possible
that Tatsuta may have synthesized regiosiomer 13 from 2-
bromo-3-hydroxybenzaldehyde 4 as depicted in Figure 3.
Br
Br
BnO
CO2Me
CO2H
BnO
CO2Me
i
OR
9
10 R = Ac,
11 R = Me
ii, iii
Br
BnO
Me
iv, v, vi
Acknowledgements
nOe
OMe
12
This work was supported by the National Research
Foundation (NRF, GUN 2053652), Pretoria, and the
University of the Witwatersrand (University Research
nOe
Scheme 3. Reagents and conditions: (i) NaOAc, Ac2O, reflux, 61%; (ii)
KOH, MeOH, rt, 100%; (iii) (MeO)2SO2, K2CO3, acetone, reflux, 98%;
(iv) LiAlH4, THF, 0 ꢁC, 99%; (v) (Cl2BrC)2, PPh3, CH2Cl2, rt, 81%;
(vi) L-Selectride, CH2Cl2, 0 ꢁC, 93%.
ꢀ
Council). Mrs. C. F. Kellock (nee Broli) and Dr. A. L.
Rousseau are thanked for conducting some of the initial
investigations.
Acetate 10 was successfully hydrolyzed with sodium or
potassium hydroxide to give the crystalline naphthol in
quantitative yield. The intermediate was methylated
under standard conditions to afford the substituted
naphthalene 11 in excellent yield. The ester substituent
of 11 was then converted into a methyl group using
conditions optimized by Bringmann et al.20 to afford 12,
characterized by rigorous NMRspectroscopy, which
References and notes
ꢀ
1. Leo, P.-M.; Morin, C.; Philouze, C. Org. Lett. 2002, 4,
2711–2714.
2. Williamson, R. T.; McDonald, L. A.; Barbieri, L. R.;
Carter, G. T. Org. Lett. 2002, 4, 4659–4662.
3. Pschorr, R. Justus Liebig’s Ann. Chem. 1912, 391, 23–39.
4. Hodgson, H. H.; Beard, H. G. J. Chem. Soc. 1925, 875–
881.
1
included NOE and a three bond HMBC H–13C NMR
5. Pandya, K. C.; Pandya, R. B. K.; Singh, R. N. J. Indian
Chem. Soc. 1952, 29, 363–367.
spectroscopy experiment. Comparison of the spectro-
scopic data of 12 with those obtained by using 8 as a
starting material by other researchers, which led to
4-(benzyloxy)-1-bromo-5-methoxy-7-methyl-naphthalene
proved to be substantially different.21
6. (a) Qiao, L.; Zhao, L.-Y.; Rong, S.-B.; Wu, X.-W.; Wang,
S.; Fujii, T.; Kazanietz, M. G.; Rauser, L.; Savage, J.;
Roth, B. L.; Flippen-Anderson, J.; Kozikowski, A. P.
Bioorg. Med. Chem. Lett. 2001, 11, 955–959; (b) Harmata,
M.; Barnes, C. L.; Rao Karra, S. R.; Elahmad, S. J. Am.
Chem. Soc. 1994, 116, 8392–8393.
7. (a) de Koning, C. B.; Michael, J. P.; van Otterlo, W. A. L.
Tetrahedron Lett. 1999, 40, 3037–3040; (b) de Koning, C.
B.; Michael, J. P.; van Otterlo, W. A. L. J. Chem. Soc.,
Perkin Trans. 1 2000, 799–811.
In conclusion, it is clear that the bromination of 1 gives
mixtures of monobrominated products. In our case we
were able to detect both the 2-bromo-5-hydroxybenz-
aldehyde and 2-bromo-3-hydroxybenzaldehyde isomers
2 and 4 in the reaction mixture, but not 3. We were also
successful in synthesizing the substituted naphthalene 12
from isomer 4. It is unlikely that the structure of the
natural medermycin is incorrect, as extensive spectro-
scopic data have been produced to verify the structure.2
On the basis of the bromination experiments conducted
in our laboratories, 2-bromo-5-hydroxybenzaldehyde 2
and 2-bromo-3-hydroxy-benzaldehyde 4 were the only
isomers that we were able to isolate in appreciable
quantities. An extensive literature search shows no
claims, apart from the work of Hodgson and Beard,4
8. Barfknecht, C. F.; Nichols, D. E. J. Med. Chem. 1971, 14,
370–372.
~
9. Matos Beja, A.; Paixao, J. A.; Ramos Silva, M.; Alte da
Veiga, L.; Rocha Gonsalves, A. M. d’A.; Serra, A. C. Acta
Cryst. 2000, C56, 354–355.
10. For the history of the isolation of medermycin see: (a)
Takano, S.; Hasuda, K.; Ito, A.; Koide, Y.; Ishii, F.;
Haneda, I.; Chihara, S.; Koyama, Y. J. Antibiot. 1976, 29,
765–768; (b) Fukushima, K.; Arai, T. Mass Spectrosc.
1979, 27, 97–105; (c) Tanaka, N.; Okabe, T.; Isono, F.;
Kashowagi, M.; Nomoto, K.; Takahashi, M.; Shimazu,
A.; Nishimura, T. J. Antibiot. 1985, 38, 1327–1332; (d)
Okabe, T.; Nomoto, K.; Funabashi, H.; Okuda, S.;
Suzuki, H.; Tanaka, N. J. Antibiot. 1985, 38, 1333–1336.
11. Synthesis of medermycin: (a) Tatsuta, K.; Ozeki, H.;
Yamaguchi, M.; Tanaka, M.; Okui, T. Tetrahedron Lett.
1990, 31, 5495–5498; (b) Tatsuta, K.; Ozeki, H.; Yama-
guchi, M.; Tanaka, M.; Okui, T.; Nakata, M. J. Antibiot.
1991, 44, 901–902.
12. (a) de Koning, C. B.; Michael, J. P.; Rousseau, A. L. J.
Chem. Soc., Perkin Trans. 1 2000, 787–797; (b) van
Otterlo, W. A. L.; Ngidi, E. L.; Coyanis, E. M.; de
Koning, C. B. Tetrahedron Lett. 2003, 44, 311–313; For a
recent review on the synthesis of naphthalenes see: (c) de
Koning, C. B.; Rousseau, A. L.; van Otterlo, W. A. L.
Tetrahedron 2003, 59, 7–36.
O
O
HO
N
HO
CHO
H
O
O
Br
O
4
O
13
OH
Figure 3. Regioisomer 13 of medermycin, which could be synthesized
from 2-bromo-3-hydroxybenzaldehyde 4.